Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Cancer
2009 Oct 15;11520:4655-66. doi: 10.1002/cncr.24532.
Show Gene links
Show Anatomy links
Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.
Thangaraju M
,
Karunakaran SK
,
Itagaki S
,
Gopal E
,
Elangovan S
,
Prasad PD
,
Ganapathy V
.
???displayArticle.abstract???
BACKGROUND: 3-bromopyruvate is an alkylating agent with antitumor activity. It is currently believed that blockade of adenosine triphosphate production from glycolysis and mitochondria is the primary mechanism responsible for this antitumor effect. The current studies uncovered a new and novel mechanism for the antitumor activity of 3-bromopyruvate.
METHODS: The transport of 3-bromopyruvate by sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8), a tumor suppressor and a sodium (Na+)-coupled, electrogenic transporter for short-chain monocarboxylates, was studied using a mammalian cell expression and the Xenopus laevis oocyte expression systems. The effect of 3-bromopyruvate on histone deacetylases (HDACs) was monitored using the lysate of the human breast cancer cell line MCF7 and human recombinant HDAC isoforms as the enzyme sources. Cell viability was monitored by fluorescence-activated cell-sorting analysis and colony-formation assay. The acetylation status of histone H4 was evaluated by Western blot analysis.
RESULTS: 3-Bromopyruvate is a transportable substrate for SLC5A8, and that transport process is Na+-coupled and electrogenic. MCF7 cells did not express SLC5A8 and were not affected by 3-bromopyruvate. However, when transfected with SLC5A8 or treated with inhibitors of DNA methylation, these cells underwent apoptosis in the presence of 3-bromopyruvate. This cell death was associated with the inhibition of HDAC1/HDAC3. Studies with different isoforms of human recombinant HDACs identified HDAC1 and HDAC3 as the targets for 3-bromopyruvate.
CONCLUSIONS: 3-Bromopyruvate was transported into cells actively through the tumor suppressor SLC5A8, and the process was energized by an electrochemical Na+ gradient. Ectopic expression of the transporter in MCF7 cells led to apoptosis, and the mechanism involved the inhibition of HDAC1/HDAC3.
Acan,
Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate.
2001, Pubmed
Acan,
Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate.
2001,
Pubmed
Cao,
Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
2008,
Pubmed
Chen,
The Warburg effect and its cancer therapeutic implications.
2007,
Pubmed
Coady,
The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter.
2004,
Pubmed
,
Xenbase
Drummond,
Clinical development of histone deacetylase inhibitors as anticancer agents.
2005,
Pubmed
Gallagher,
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
2007,
Pubmed
Ganapathy,
Sodium-coupled monocarboxylate transporters in normal tissues and in cancer.
2008,
Pubmed
Ganapathy,
Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.
2009,
Pubmed
Gatenby,
Why do cancers have high aerobic glycolysis?
2004,
Pubmed
Geschwind,
Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma.
2004,
Pubmed
Geschwind,
Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.
2002,
Pubmed
Goffin,
DNA methyltransferase inhibitors-state of the art.
2002,
Pubmed
Gopal,
Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family.
2005,
Pubmed
,
Xenbase
Gopal,
Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate.
2004,
Pubmed
,
Xenbase
Gopal,
Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract.
2007,
Pubmed
,
Xenbase
Gupta,
SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter.
2006,
Pubmed
Itagaki,
Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8).
2006,
Pubmed
,
Xenbase
Karunakaran,
Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy.
2008,
Pubmed
,
Xenbase
Kim,
Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.
2007,
Pubmed
Kim,
Cancer's molecular sweet tooth and the Warburg effect.
2006,
Pubmed
Ko,
Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.
2001,
Pubmed
Ko,
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.
2004,
Pubmed
Li,
SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers.
2003,
Pubmed
Marks,
Histone deacetylases and cancer: causes and therapies.
2001,
Pubmed
Mathupala,
Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.
2006,
Pubmed
Miyauchi,
Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids.
2004,
Pubmed
,
Xenbase
Pedersen,
The cancer cell's "power plants" as promising therapeutic targets: an overview.
2007,
Pubmed
Ristow,
Oxidative metabolism in cancer growth.
2006,
Pubmed
Stubbs,
Causes and consequences of tumour acidity and implications for treatment.
2000,
Pubmed
Thangaraju,
SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases.
2006,
Pubmed
Thangaraju,
Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3.
2009,
Pubmed
Thangaraju,
Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer.
2008,
Pubmed
Ullah,
The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism.
2006,
Pubmed
Vali,
Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.
2007,
Pubmed
WARBURG,
On the origin of cancer cells.
1956,
Pubmed
